Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLI1 | Q01543 | 5/20 | 0.78 |
| ▸ | EWSR1 | Q01844 | 5/20 | 0.78 |
| ▸ | ERG | P11308 | 1/20 | 0.78 |
| ▸ | ETV1 | P50549 | 1/20 | 0.78 |
| ▸ | MMP2 | P08253 | 3/20 | 0.54 |
| ▸ | MMP9 | P14780 | 3/20 | 0.54 |
| ▸ | MMP8 | P22894 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29399443 | 0.88 | FLI1 (1.00) | FLI1EWSR1ERGETV1MMP2 | |
| SCHEMBL19829781 | 0.88 | FLI1 (1.00) | FLI1EWSR1ERGETV1MMP2 | |
| SCHEMBL3486735 | 0.88 | FLI1 (1.00) | FLI1EWSR1ERGETV1MMP2 | |
| SCHEMBL19829782 | 0.88 | FLI1 (1.00) | FLI1EWSR1ERGETV1MMP2 | |
| SCHEMBL29810794 | 0.79 | FLI1 (0.83) | FLI1EWSR1ERGETV1MMP2 | |
| SCHEMBL17679820 | 0.79 | FLI1 (0.83) | FLI1EWSR1ERGETV1MMP2 | |
| SCHEMBL17679823 | 0.79 | FLI1 (0.83) | FLI1EWSR1ERGETV1MMP2 | |
| SCHEMBL17669251 | 0.79 | FLI1 (0.83) | FLI1EWSR1ERGETV1MMP2 | |
| SCHEMBL15337311 | 0.77 | FLI1 (0.80) | FLI1EWSR1ERGETV1MMP2 | |
| SCHEMBL15337262 | 0.76 | FLI1 (0.74) | FLI1EWSR1ERGETV1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3795563-B1 | INDOLINE ANALOGS AND USES THEREOF | ONCTERNAL THERAPEUTICS INC (US) | 2024-07-17 | — | — | EP | disclosed |
| EP-3795563-A1 | INDOLINE ANALOGS AND USES THEREOF | Oncternal Therapeutics, Inc. (US) | 2021-03-24 | — | — | EP | disclosed |
| US-10711008-B2 | Indoline analogs and uses thereof | Oncternal Therapeutics, Inc. (US) | 2020-07-14 | — | — | US | disclosed |
| EP-3436434-B1 | INDOLINE ANALOGS AND USES THEREOF | ONCTERNAL THERAPEUTICS INC (US) | 2020-07-08 | — | — | EP | disclosed |
| US-20190337951-A1 | INDOLINE ANALOGS AND USES THEREOF | GEORGETOWN UNIVERSITY | 2019-11-07 | — | — | US | disclosed |
| US-10351569-B2 | Indoline analogs and uses thereof | Oncternal Therapeutics, Inc. (US) | 2019-07-16 | — | — | US | disclosed |
| US-20170349600-A1 | INDOLINE ANALOGS AND USES THEREOF | GEORGETOWN UNIVERSITY | 2017-12-07 | — | — | US | disclosed |
| US-20170349600-A1 | INDOLINE ANALOGS AND USES THEREOF | GEORGETOWN UNIVERSITY | 2017-12-07 | — | — | US | disclosed |
| US-9822122-B2 | Indoline analogs and uses thereof | Oncternal Therapeutics, Inc. (US) | 2017-11-21 | — | — | US | disclosed |
| US-9822122-B2 | Indoline analogs and uses thereof | Oncternal Therapeutics, Inc. (US) | 2017-11-21 | — | — | US | disclosed |
| WO-2017172368-A1 | INDOLINE ANALOGS AND USES THEREOF | Oncternal Therapeutics, Inc. (US) | 2017-10-05 | — | — | WO | disclosed |
| US-20170283420-A1 | INDOLINE ANALOGS AND USES THEREOF | GEORGETOWN UNIVERSITY | 2017-10-05 | — | — | US | disclosed |
| US-20170283420-A1 | INDOLINE ANALOGS AND USES THEREOF | GEORGETOWN UNIVERSITY | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190337951-A1 | INDOLINE ANALOGS AND USES THEREOF | FLI1, EWSR1, IKZF1 | FLI1 1/4885EWSR1 2/4885ERG 5/4885 |
| US-10711008-B2 | Indoline analogs and uses thereof | FLI1, EWSR1, IKZF1 | FLI1 1/4885EWSR1 2/4885ERG 5/4885 |
| US-10351569-B2 | Indoline analogs and uses thereof | FLI1, EWSR1, IKZF1 | FLI1 1/4885EWSR1 2/4885ERG 5/4885 |
| US-20170283420-A1 | INDOLINE ANALOGS AND USES THEREOF | FLI1, EWSR1, IKZF1 | FLI1 1/4885EWSR1 2/4885ERG 5/4885 |
| US-20170349600-A1 | INDOLINE ANALOGS AND USES THEREOF | FLI1, EWSR1, IKZF1 | FLI1 1/4885EWSR1 2/4885ERG 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.